Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Lexeo Therapeutics announced multiple presentations at the 29th ASGCT Annual Meeting featuring new data on its cardiac gene therapy pipeline, including TNNI3 cardiomyopathy and Friedreich ataxia treatments, as well as advances in AAV manufacturing technology. The presentations highlight the company's innovative approaches and ongoing clinical trial…